Fogelholm R, Murros K
Department of Neurology, Central Hospital of Central Finland, Jyväskylä.
Headache. 1992 Nov;32(10):509-13. doi: 10.1111/j.1526-4610.1992.hed3210509.x.
The efficacy of tizanidine in chronic tension-type headache was compared with placebo in a randomized, double-blind and cross-over study in 37 women aged 20 to 59 years with a history of headache for 7 months to 30 years (median 5 years). The treatment periods were 6 weeks with an intervening 2 week wash-out period. The treatment was started with 6 mg/day divided into three doses, and the daily dose could be increased to 18 mg/day depending on the treatment response. The effect of the treatment was measured by visual analogue scale, verbal rating scale, number of days free of headache, number of analgesics needed, and the dose of trial medication needed. In all these measurements, tizanidine was statistically significantly more effective than placebo. The pre-trial Beck Depression Inventory score did not predict the response to treatment, neither did the level of electromyographic activity of the trapezius muscle. Side-effects, drowsiness and dry mouth were significantly more common during tizanidine treatment but they were usually mild. The results of the present trial suggest that tizanidine is effective in the treatment of chronic tension-type headache in women.
在一项随机、双盲、交叉研究中,将替扎尼定治疗慢性紧张型头痛的疗效与安慰剂进行了比较。该研究纳入了37名年龄在20至59岁之间、头痛病史为7个月至30年(中位数5年)的女性。治疗期为6周,中间有2周的洗脱期。治疗从每日6毫克开始,分三次服用,根据治疗反应,每日剂量可增至18毫克。通过视觉模拟量表、言语评定量表、无头痛天数、所需止痛药物数量以及所需试验药物剂量来衡量治疗效果。在所有这些测量中,替扎尼定在统计学上比安慰剂显著更有效。试验前的贝克抑郁量表评分无法预测治疗反应,斜方肌的肌电图活动水平也不能预测。在替扎尼定治疗期间,副作用、嗜睡和口干明显更为常见,但通常较为轻微。本试验结果表明,替扎尼定对女性慢性紧张型头痛有效。